Esperion Therapeutic. Inc.

ARCHIMED funds have signed a takeover agreement for Esperion that values the company at up to about $1.1 billion. Shareholders will receive $3.16 in cash per share plus non-tradable milestone rights (CVR) of up to $100 million, tied to future U.S. net revenues of certain products. The cash payment represents a 58% premium to the April 30, 2026 closing price; the Esperion share currently trades well below the offer price. The board recommends acceptance, closing is expected in Q3 2026; after the acquisition Esperion will be taken private and its stock will be removed from NASDAQ. » Więcej na de.investing.com

Esperion sold funds from Athyrium the claim on tiered royalties for Otsuka’s bempedoic acid products in Japan for $50 million. Athyrium will receive, starting January 1, 2026, tiered royalties of 12–33% plus milestone payments until it recoups 2.0× its investment, after which the rights revert to Esperion. Esperion plans to use the proceeds to finance the acquisition of Corstasis Therapeutics, which markets the approved bumetanide nasal spray Enbumyst. » Więcej na de.investing.com

Esperion recorded total revenue of $408 million in 2025 (+38%) and a 34% increase in prescriptions. The company announced the acquisition of Corstasis Biotherapeutics, including the nasal loop diuretic Enbumyst, with closing expected in early April. International partnerships with Daiichi Sankyo and Otsuka and the "Vision 2040" strategy are intended to further expand the bempedoic acid franchise and the ACLY pipeline. Esperion ended 2025 with $168 million in cash and expects 2026 to be its most successful year to date. » Więcej na de.investing.com